Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1152 part A · 1 trial · 1 indication
Safety and tolerability will be assessed through the incidence of adverse events. Adverse events will include significant findings on vital signs, clinical chemistry/haematology, coagulation parameters and electrocardiograms (ECGs).
| Arm | Type | Description |
|---|---|---|
| AZD1152 | EXPERIMENTAL | AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment) |
| Name | Type | Description |
|---|---|---|
| AZD1152 part A | DRUG | 48-hour continuous intravenous infusion |
| AZD1152 part B | DRUG | 2-hour intravenous infusion |
Inclusion Criteria: * Histological or cytological confirmation of a solid, malignant tumour * At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Exclusion Criteria: * Participation in an investigational drug stud...
Top 20 of 45 competitors
AZD1152 part A is an investigational small molecule being studied for the treatment of tumors. It is in Phase 1 clinical development for oncology indications. The drug is not approved and remains under investigation in clinical trials.
AZD1152 part A is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker AZN. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with advanced solid malignancies.
AZD1152 part A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial for the treatment of tumors.
AZD1152 part A has been studied in one clinical trial with the identifier NCT00338182, titled 'AZD1152 in Patients With Advanced Solid Malignancies.' This Phase 1 trial was completed and enrolled 43 participants in the United States. The trial was uncontrolled and not randomized or double-blind.
AZD1152 part A is a component of the drug candidate AZD1152. The clinical trial NCT00338182 evaluated AZD1152 in patients with advanced solid malignancies. The specific designation 'part A' refers to a portion of the study, but the drug substance is AZD1152.